A Phase 2/3 interventional study of efgartigimod PH20 SC and placebo in Bullous Pemphigoid, sponsored by argenx. Completed at 129 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-23.
Sponsored by argenx · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Pemphigoid, Bullous with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Pemphigoid, Bullous · United States.
Among the 15 studies in Pemphigoid, Bullous with a site in United States, this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2022, is one of 2 in phase 2/3, and was the 13th registered.
64 studies on the registry are indexed under Pemphigoid, Bullous; 8 are open to participants now.
Browse Pemphigoid, Bullous studies →2 of the 15 studies in Pemphigoid, Bullous with a site in United States are open now. Recruiting first, the newest first:
Chugai Pharmaceutical · Sites in United States, Australia, Austria and 17 more countries
Ages 18–85
University of Pennsylvania · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Pemphigoid, Bullous studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 6 · Phase 4 1
First in 2005; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is above the median of 30 across 39 interventional studies indexed under Pemphigoid, Bullous.
Median enrollment 11 across the 13 interventional studies, 86 across the 2 observational. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 15 have an industry lead sponsor. The 10 most frequent:
argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.
argenx has 2 studies filed under Pemphigoid, Bullous — fewer than ten, so there is no comparison to draw.
1 of the studies in Pemphigoid, Bullous with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Pemphigoid, Bullous with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
ARGX-113-2009 is an operationally seamless 2-part, phase 2/3, prospective, global, multicenter, randomized, double-blinded, placebo-controlled study to investigate the efficacy, safety, tolerability, immunogenicity, participant-reported outcome measures (including those assessing participant QoL), PK, and PD of efgartigimod PH20 SC administered via subcutaneous (SC) injection in adult participants with moderate to severe BP. This study intends to demonstrate that efgartigimod is an effective and safe treatment for BP, providing participants with control of disease activity (CDA) and eventually remission while reducing their cumulative exposure to OCS.
study will consist of 2 parts:
An interim analysis will be performed during part A (on data obtained through week 26 for all Part A participants) to assess the primary endpoint and several secondary endpoints, confirm the appropriate sample size for part B of the study, and determine whether the efficacy results observed through week 26 of part A warrant continued study of efgartigimod PH20 SC for the treatment of participants with BP (futility analysis).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The participant is willing and able to do the following:
The full list of inclusion criteria can be found in the protocol.
Exclusion Criteria:
The full list of exclusion criteria can be found in the protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
participants receiving efgartigimod PH20 SC on top of Prednisone
Biological: efgartigimod PH20 SC · Drug: Prednisone
participants receiving placebo PH20 SC on top of Prednisone
Other: placebo · Drug: Prednisone
Drug pages: Efgartigimod alfa · Hyaluronidase (human recombinant)
Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer
Subcutaneous injection of placebo coformulated with rHuPH20, a permeation enhancer
Oral Prednisone
Number of Participants With CRoff at Week 36
CRoff = complete remission while receiving efgartigimod PH20 SC or placebo and being off oral corticosteroid therapy for at least 8 weeks. Complete remission is defined as the absence of new lesions, complete healing of existing lesions and absence of pruritus.
Time frame: at week 36
Cumulative OCS Dose
OCS = oral corticosteroid
Time frame: up to week 36
Number of Participants Who Achieve an IGA-BP Score of 0 While Off OCS Therapy for ≥8 Weeks at Week 36
IGA-BP = Investigator Global Assessment of Bullous Pemphigoid. IGA-BP scores range from 0-4, with a higher score representing severe BP. OCS = oral corticosteroid
Time frame: at week 36
Number of Participants With CDA Who Remained Free of Relapse Through Week 36
Control of disease activity (CDA) is defined as the point at which new lesions ceased to form, established lesions began to heal, and pruritic symptoms started to abate. Relapse is defined as the appearance of 3 or more new lesions a month or at least 1 large lesion that did not heal within 1 week, or extension of established lesions or daily pruritus in a participant who had achieved CDA.
Time frame: up to week 36
Number of Participants With CRmin at Week 36
CRmin = complete remission receiving minimal oral corticosteroids for at least 8 weeks. Minimal oral corticosteroid (OCS) therapy is defined as ≤0.1 mg/kg/day of prednisone (or equivalent).
Time frame: at week 36
Change From Baseline to Week 36 in the 24-Hour Average Itch NRS Score
Itch NRS = Itch Numerical Rating Scale. The Itch NRS scores range from 0-10 with 10 representing the worst imaginable itch.
Time frame: up to week 36
Changes From Baseline in the BPDAI Total Activity Score
BPDAI = Bullous Pemphigoid Disease Area Index (BPDAI) Total Activity Score is a tool to objectively measure disease activity. BPDAI scores range from 0 to 360 with a higher score indicating more severe disease (max 240 for total skin activity and 120 for mucosal activity).
Time frame: up to week 36
Time to CDA
CDA = control of disease activity, the point at which new lesions ceased to form, established lesions began to heal, and pruritic symptoms started to abate.
Time frame: up to week 36
Time to CR
CR = complete remission, the absence of new lesions, complete healing of existing lesions, and absence of pruritus.
Time frame: up to week 36
Time to CRmin
CRmin = complete remission, the absence of new lesions, complete healing of existing lesions, and absence of pruritus while being on minimal dose of OCS for ≥8 Weeks. OCS = oral corticosteroid. Minimal OCS therapy is defined as an oral prednisone dosage of ≤0.10 mg/kg/day (or equivalent).
Time frame: up to week 36
Time to CRoff/PRoff
CRoff= complete remission (the absence of new lesions, complete healing of existing lesions, and absence of pruritus) while receiving efgartigimod PH20 SC or placebo and being off oral corticosteroid therapy for at least 8 weeks. PRoff = partial remission (the presence of only new transient lesions) while receiving efgartigimod PH20 SC or placebo and being off oral corticosteroid therapy for at least 8 weeks.
Time frame: up to week 36
Time to CRoff
CRoff is defined as the absence of new lesions, complete healing of existing lesions, and absence of pruritus while being off OCS therapy for ≥8 weeks.
Time frame: up to week 36
Time From CDA to Achieve Relapse
CDA is defined as the point at which new lesions ceased to form, established lesions began to heal, and pruritic symptoms started to abate. Relapse is defined as the appearance of 3 or more new lesions a month or at least 1 large lesion that did not heal within 1 week, or extension of established lesions or daily pruritus in a participant who had achieved CDA.
Time frame: up to week 36
Number of Participants Who Receive Rescue Therapy Before Week 36
Time frame: at week 36
The AIS From the GTI
The Aggregate Improvement Score (AIS) from the Glucocorticoid Toxicity Index (GTI) can range from -346 to 439 with a higher score representing greater corticosteroid toxicity. If a study drug is effective at lowering greater corticosteroid toxicity over time, the score will be lower.
Time frame: up to week 36
The CWS From the GTI
The Cumulative Worsening Score (CWS) from the Glucocorticoid Toxicity Index (GTI) can range from 0 to 439 with a higher score representing greater corticosteroid toxicity.
Time frame: up to week 36
EQ-5D-5L VAS Scores Over Time
The EuroQol 5-Dimension 5-Level Visual Analog Scale (EQ-5D-5L VAS) scores range from 0-100 with 0 representing the worst health.
Time frame: up to week 36
DLQI Scores Over Time
Dermatology Life Quality Index (DLQI) assess the participant's perception of the impact of skin diseases on different aspects of their health-related QoL. Scores range from 0 to 30 with a higher score representing a worse quality of life.
Time frame: up to week 36
ABQoL Scores Over Time
Autoimmune Bullous Disease Quality of Life Index (ABQoL) questionnaire assesses the impact of Autoimmune Bullous Disease and their therapies on the daily life of patients. Scores range from 0 to 51 with a higher score representing a worse quality of life.
Time frame: up to week 36
Efgartigimod Serum Concentrations
Time frame: up to week 36
Percent Change of Total IgG Serum Levels From Baseline Over Time
Time frame: up to 36 weeks
Percent Change of Anti-BP180 and Anti-BP230 Antibodies From Baseline Over Time
Time frame: up to 36 weeks
Incidence of Antidrug Antibodies Against Efgartigimod and Antibodies Produced Against rHuPH20
Time frame: up to 46 weeks
Number of Participants (or Their Caregivers) Who Are Determined by Site Staff to be Sufficiently Competent in (Self-)Administering Efgartigimod PH20 SC
Time frame: up to week 32
| Milestone | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Started | 50 | 48 |
| Completed | 35 | 35 |
| Not completed | 15 | 13 |
| Withdrew: Adverse event | 1 | 4 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Lack of efficacy | 1 | 2 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Physician decision | 4 | 0 |
| Withdrew: Treatment unblinded | 0 | 1 |
| Withdrew: Withdrawal by subject | 5 | 4 |
CRoff = complete remission while receiving efgartigimod PH20 SC or placebo and being off oral corticosteroid therapy for at least 8 weeks. Complete remission is defined as the absence of new lesions, complete healing of existing lesions and absence of pruritus.
| Participants | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Number of Participants With CRoff at Week 36 | 8 | 2 |
OCS = oral corticosteroid
| mg/kg/day | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Cumulative OCS Dose | 0.242 ± 0.138 | 0.289 ± 0.173 |
IGA-BP = Investigator Global Assessment of Bullous Pemphigoid. IGA-BP scores range from 0-4, with a higher score representing severe BP. OCS = oral corticosteroid
| Participants | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Number of Participants Who Achieve an IGA-BP Score of 0 While Off OCS Therapy for ≥8 Weeks at Week 36 | 9 | 3 |
Control of disease activity (CDA) is defined as the point at which new lesions ceased to form, established lesions began to heal, and pruritic symptoms started to abate. Relapse is defined as the appearance of 3 or more new lesions a month or at least 1 large lesion that did not heal within 1 week, or extension of established lesions or daily pruritus in a participant who had achieved CDA.
| Participants | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Number of Participants With CDA Who Remained Free of Relapse Through Week 36 | 7 | 8 |
CRmin = complete remission receiving minimal oral corticosteroids for at least 8 weeks. Minimal oral corticosteroid (OCS) therapy is defined as ≤0.1 mg/kg/day of prednisone (or equivalent).
| Participants | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Number of Participants With CRmin at Week 36 | 8 | 3 |
Itch NRS = Itch Numerical Rating Scale. The Itch NRS scores range from 0-10 with 10 representing the worst imaginable itch.
| score on a scale | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Change From Baseline to Week 36 in the 24-Hour Average Itch NRS Score | -4.4 ± 3.35 | -2.4 ± 4.26 |
BPDAI = Bullous Pemphigoid Disease Area Index (BPDAI) Total Activity Score is a tool to objectively measure disease activity. BPDAI scores range from 0 to 360 with a higher score indicating more severe disease (max 240 for total skin activity and 120 for mucosal activity).
| score on a scale | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Changes From Baseline in the BPDAI Total Activity Score | -43.13 ± 19.633 | -43.56 ± 32.584 |
CDA = control of disease activity, the point at which new lesions ceased to form, established lesions began to heal, and pruritic symptoms started to abate.
| days | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Time to CDA | 16.0 (10.0 to 17.0) | 15.0 (13.0 to 22.0) |
CR = complete remission, the absence of new lesions, complete healing of existing lesions, and absence of pruritus.
| days | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Time to CR | 134.0 (85.0 to NA) | 99.0 (57.0 to 225.0) |
CRmin = complete remission, the absence of new lesions, complete healing of existing lesions, and absence of pruritus while being on minimal dose of OCS for ≥8 Weeks. OCS = oral corticosteroid. Minimal OCS therapy is defined as an oral prednisone dosage of ≤0.10 mg/kg/day (or equivalent).
| days | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Time to CRmin | NA (247.0 to NA) | NA (NA to NA) |
CRoff= complete remission (the absence of new lesions, complete healing of existing lesions, and absence of pruritus) while receiving efgartigimod PH20 SC or placebo and being off oral corticosteroid therapy for at least 8 weeks. PRoff = partial remission (the presence of only new transient lesions) while receiving efgartigimod PH20 SC or placebo and being off oral corticosteroid therapy for at least 8 weeks.
| days | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Time to CRoff/PRoff | NA (NA to NA) | NA (NA to NA) |
CRoff is defined as the absence of new lesions, complete healing of existing lesions, and absence of pruritus while being off OCS therapy for ≥8 weeks.
| days | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Time to CRoff | NA (NA to NA) | NA (NA to NA) |
CDA is defined as the point at which new lesions ceased to form, established lesions began to heal, and pruritic symptoms started to abate. Relapse is defined as the appearance of 3 or more new lesions a month or at least 1 large lesion that did not heal within 1 week, or extension of established lesions or daily pruritus in a participant who had achieved CDA.
| days | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Time From CDA to Achieve Relapse | 114.0 (78.0 to 160.0) | 105.0 (71.0 to 163.0) |
| Participants | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Number of Participants Who Receive Rescue Therapy Before Week 36 | 19 | 18 |
The Aggregate Improvement Score (AIS) from the Glucocorticoid Toxicity Index (GTI) can range from -346 to 439 with a higher score representing greater corticosteroid toxicity. If a study drug is effective at lowering greater corticosteroid toxicity over time, the score will be lower.
| score on a scale | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| The AIS From the GTI | 5.7 ± 56.98 | 10.9 ± 45.42 |
The Cumulative Worsening Score (CWS) from the Glucocorticoid Toxicity Index (GTI) can range from 0 to 439 with a higher score representing greater corticosteroid toxicity.
| score on a scale | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| The CWS From the GTI | 56.1 ± 40.71 | 47.5 ± 46.68 |
The EuroQol 5-Dimension 5-Level Visual Analog Scale (EQ-5D-5L VAS) scores range from 0-100 with 0 representing the worst health.
| score on a scale | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| EQ-5D-5L VAS Scores Over Time | 12.7 ± 15.94 | 4.5 ± 24.44 |
Dermatology Life Quality Index (DLQI) assess the participant's perception of the impact of skin diseases on different aspects of their health-related QoL. Scores range from 0 to 30 with a higher score representing a worse quality of life.
| score on a scale | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| DLQI Scores Over Time | -7.3 ± 6.25 | -6.7 ± 7.14 |
Autoimmune Bullous Disease Quality of Life Index (ABQoL) questionnaire assesses the impact of Autoimmune Bullous Disease and their therapies on the daily life of patients. Scores range from 0 to 51 with a higher score representing a worse quality of life.
| score on a scale | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| ABQoL Scores Over Time | -12.3 ± 6.44 | -12.0 ± 10.92 |
| ug/mL | Efgartigimod PH20 SC |
|---|---|
| Week 1 | 35.7 ± 13.6 |
| Day 10 | 96.4 ± 23.9 |
| Week 2 | 37.3 ± 12.5 |
| Week 4 | 26.0 ± 11.0 |
| Week 8 | 25.8 ± 10.5 |
| Week 12 | 24.4 ± 8.92 |
| Week 16 | 24.3 ± 8.51 |
| Week 20 | 23.9 ± 9.12 |
| Week 24 | 24.3 ± 9.98 |
| Week 26 | 24.6 ± 10.2 |
| Week 28 | 23.3 ± 10.3 |
| Week 32 | 26.1 ± 11.3 |
| Week 36 | 22.2 ± 8.59 |
| percent change | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Percent Change of Total IgG Serum Levels From Baseline Over Time | -46.91 ± 42.244 | -7.65 ± 25.374 |
| Percent change in RU/mL | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Percent change of Anti-BP180 antibodies from baseline over time | -58.58 ± 56.983 | -57.98 ± 33.470 |
| Percent change of Anti-BP230 antibodies from baseline over time | -46.72 ± 35.950 | -50.95 ± 28.617 |
| Participants | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| ADA against efgartigimod | 2 | 2 |
| Antibodies against rHuPH20 | 9 | 0 |
| Participants | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| Participants | 5 | 4 |
| Caregivers | 2 | 3 |
Collected over up to 46 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Efgartigimod PH20 SC | 1/50 (2%) | 12/50 (24%) | 47/50 (94%) |
| Placebo PH20 SC | 2/48 (4.2%) | 12/48 (25%) | 46/48 (95.8%) |
| Event | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| DEEP VEIN THROMBOSISVascular disorders | 0/50 | 2/48 |
| CONDITION AGGRAVATEDGeneral disorders | 2/50 | 0/48 |
| PNEUMONIAInfections and infestations | 2/50 | 0/48 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 0/50 | 1/48 |
| ATRIAL FIBRILLATIONCardiac disorders | 1/50 | 1/48 |
| CARDIAC FAILURECardiac disorders | 0/50 | 1/48 |
| CORONARY ARTERY STENOSISCardiac disorders | 0/50 | 1/48 |
| SINUS NODE DYSFUNCTIONCardiac disorders | 0/50 | 1/48 |
| CUSHING'S SYNDROMEEndocrine disorders | 0/50 | 1/48 |
| NON-CARDIAC CHEST PAINGeneral disorders | 0/50 | 1/48 |
| Event | Efgartigimod PH20 SC | Placebo PH20 SC |
|---|---|---|
| INSOMNIAPsychiatric disorders | 7/50 | 8/48 |
| INCREASED TENDENCY TO BRUISEBlood and lymphatic system disorders | 5/50 | 7/48 |
| HEADACHENervous system disorders | 7/50 | 2/48 |
| URINARY TRACT INFECTIONInfections and infestations | 5/50 | 6/48 |
| COUGHRespiratory, thoracic and mediastinal disorders | 6/50 | 0/48 |
| HYPERTENSIONVascular disorders | 6/50 | 2/48 |
| OEDEMA PERIPHERALGeneral disorders | 5/50 | 5/48 |
| BACK PAINMusculoskeletal and connective tissue disorders | 5/50 | 5/48 |
| PRURITUSSkin and subcutaneous tissue disorders | 4/50 | 5/48 |
| LYMPHOPENIABlood and lymphatic system disorders | 5/50 | 3/48 |
| Age, Continuous(years) | Efgartigimod PH20 SC | Placebo PH20 SC | Total |
|---|---|---|---|
| Mean | 71.0 ± 12.02 | 70.9 ± 9.37 | 70.9 ± 10.75 |
| Age, Customized(Participants) | Efgartigimod PH20 SC | Placebo PH20 SC | Total |
|---|---|---|---|
| 18 - <65 years | 12 | 11 | 23 |
| 65 - <75 years | 18 | 17 | 35 |
| 75 - <85 years | 15 | 17 | 32 |
| >=85 years | 5 | 3 | 8 |
| Sex: Female, Male(Participants) | Efgartigimod PH20 SC | Placebo PH20 SC | Total |
|---|---|---|---|
| Female | 37 | 35 | 72 |
| Male | 13 | 13 | 26 |
| Race/Ethnicity, Customized(Participants) | Efgartigimod PH20 SC | Placebo PH20 SC | Total |
|---|---|---|---|
| AMERICAN INDIAN OR ALASKA NATIVE | 1 | 0 | 1 |
| ASIAN | 8 | 9 | 17 |
| MULTIPLE | 1 | 0 | 1 |
| WHITE | 40 | 39 | 79 |
| Race/Ethnicity, Customized(Participants) | Efgartigimod PH20 SC | Placebo PH20 SC | Total |
|---|---|---|---|
| HISPANIC OR LATINO | 1 | 0 | 1 |
| NOT HISPANIC OR LATINO | 49 | 48 | 97 |
Showing the first 100 of 129 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2022 to primary completion in Sep 2024, 27 months.
Results were first posted in Oct 2025, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Efgartigimod alfa · Hyaluronidase (human recombinant)